Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

1.

Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.

Bordi P, Tiseo M, Buti S, Regolisti G, Ardizzoni A.

Tumori. 2015 Feb 20;0(0):0. doi: 10.5301/tj.5000249. [Epub ahead of print]

PMID:
25702667
[PubMed - as supplied by publisher]
2.

Concomitant EGFR and KRAS mutations in ALK rearranged lung cancer.

Rossi G, Baldi L, Barbieri F, Bertolini F, Tiseo M.

Ann Oncol. 2015 Feb 10. pii: mdv067. [Epub ahead of print] No abstract available.

PMID:
25669831
[PubMed - as supplied by publisher]
3.

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.

Tiseo M, Bersanelli M, Perrone F, Tamborini E, Settanni G, Busico A, Rossi G, Ardizzoni A, Pelosi G.

Lung Cancer. 2015 Feb;87(2):204-6. doi: 10.1016/j.lungcan.2014.12.008. Epub 2014 Dec 19.

PMID:
25555368
[PubMed - in process]
4.

Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.

Bordi P, Tiseo M, Barbieri F, Bavieri M, Sartori G, Marchetti A, Buttitta F, Bortesi B, Ambrosini-Spaltro A, Gnetti L, Silini EM, Ardizzoni A, Rossi G.

Lung Cancer. 2014 Dec;86(3):324-8. doi: 10.1016/j.lungcan.2014.10.002. Epub 2014 Oct 12.

PMID:
25453846
[PubMed - in process]
5.

Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.

Tiseo M, Boni L, Ambrosio F, Camerini A, Vitale MG, Baldini E, Cinieri S, Zanelli F, Defraia E, Passalacqua R, Crino L, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Riccardi F, Ardizzoni A; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Clin Lung Cancer. 2015 Jan;16(1):67-70. doi: 10.1016/j.cllc.2014.09.001. Epub 2014 Sep 28.

PMID:
25450879
[PubMed - in process]
6.

First-line chemotherapy treatment of advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?

Tiseo M, Ardizzoni A, Boni L.

J Thorac Oncol. 2014 Nov;9(11):e82. doi: 10.1097/JTO.0000000000000272. No abstract available.

PMID:
25436810
[PubMed - in process]
7.

MET and Small-Cell Lung Cancer.

Gelsomino F, Rossi G, Tiseo M.

Cancers (Basel). 2014 Oct 13;6(4):2100-15. doi: 10.3390/cancers6042100. Review.

PMID:
25314153
[PubMed]
Free PMC Article
8.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F.

Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16.

PMID:
25242668
[PubMed - in process]
9.

CT-guided biopsy of pulmonary nodules: is pulmonary hemorrhage a complication or an advantage?

De Filippo M, Saba L, Silva M, Zagaria R, Concari G, Nizzoli R, Bozzetti C, Tiseo M, Ardizzoni A, Lipia S, Paladini I, Macarini L, Carrafiello G, Brunese L, Rotondo A, Rossi C.

Diagn Interv Radiol. 2014 Sep-Oct;20(5):421-5. doi: 10.5152/dir.2014.14019.

PMID:
25163758
[PubMed - in process]
Free Article
10.

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan.

Tiseo M, Buti S, Boni L, Mattioni R, Ardizzoni A.

Lung Cancer. 2014 Oct;86(1):91-5. doi: 10.1016/j.lungcan.2014.07.022. Epub 2014 Aug 2.

PMID:
25130081
[PubMed - in process]
11.

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, Marchetti A, Crinò L.

Clin Lung Cancer. 2014 Nov;15(6):470-4. doi: 10.1016/j.cllc.2014.06.004. Epub 2014 Jun 24. No abstract available.

PMID:
25087901
[PubMed - in process]
12.

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

Buti S, Bersanelli M, Tiseo M, Ardizzoni A, Musolino A.

Lancet Oncol. 2014 Jul;15(8):e304. doi: 10.1016/S1470-2045(14)70242-6. No abstract available.

PMID:
24988929
[PubMed - indexed for MEDLINE]
13.

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.

Ardizzoni A, Tiseo M, Boni L.

Eur J Cancer. 2014 Sep;50(13):2211-8. doi: 10.1016/j.ejca.2014.06.002. Epub 2014 Jun 26.

PMID:
24981975
[PubMed - indexed for MEDLINE]
14.

Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis.

Bersanelli M, Tiseo M, Artioli F, Lucchi L, Ardizzoni A.

Anticancer Res. 2014 Jun;34(6):3185-8.

PMID:
24922692
[PubMed - indexed for MEDLINE]
15.

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.

Cretella D, Saccani F, Quaini F, Frati C, Lagrasta C, Bonelli M, Caffarra C, Cavazzoni A, Fumarola C, Galetti M, La Monica S, Ampollini L, Tiseo M, Ardizzoni A, Petronini PG, Alfieri RR.

Mol Cancer. 2014 Jun 5;13:143. doi: 10.1186/1476-4598-13-143.

PMID:
24898067
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report.

Bordi P, Tiseo M, Bortesi B, Naldi N, Buti S, Ardizzoni A.

Tumori. 2014 Jan-Feb;100(1):e20-3. doi: 10.1700/1430.15832.

PMID:
24675505
[PubMed - indexed for MEDLINE]
17.

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).

Tiseo M, Andreoli R, Gelsomino F, Mozzoni P, Azzoni C, Bartolotti M, Bortesi B, Goldoni M, Silini EM, De Palma G, Mutti A, Ardizzoni A.

Lung Cancer. 2014 Feb;83(2):265-71. doi: 10.1016/j.lungcan.2013.12.001. Epub 2013 Dec 12.

PMID:
24388705
[PubMed - indexed for MEDLINE]
18.

Fishing for ALK with immunohistochemistry may predict response to crizotinib.

Bavieri M, Tiseo M, Lantuejoul S, McLeer-Florin A, Lasagni A, Fantini R, Rossi G.

Tumori. 2013 Sep-Oct;99(5):e229-32. doi: 10.1700/1377.15321.

PMID:
24362875
[PubMed - indexed for MEDLINE]
19.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Review.

PMID:
24355409
[PubMed - indexed for MEDLINE]
20.

Grading the neuroendocrine tumors of the lung: an evidence-based proposal.

Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, Campanini N, Carbognani P, De Pas TM, Galetta D, Granone PL, Righi L, Rusca M, Spaggiari L, Tiseo M, Viale G, Volante M, Papotti M, Pelosi G.

Endocr Relat Cancer. 2013 Dec 16;21(1):1-16. doi: 10.1530/ERC-13-0246. Print 2014 Feb.

PMID:
24344249
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk